Pricing Log in Create free account
Friday 6 November 2026 Export ZBH’s income statement to Excel — free account

Zimmer Biomet Holdings, Inc.

ZBH Healthcare Medical Devices

Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024.

Revenue
+3.07%
EPS
−13.5%
Free cash flow
+29.8%
Total debt
−7.50%

Quarter to September 2026, against a year earlier

105.28 1.57 −1.47%
Market cap
$20.4B
P/E
26.5×
Fwd P/E
18.9×
Dividend yield
0.91%
F-score
6/9
Altman Z
2.38
Beneish M
−2.59
Dividend safety
72/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Zimmer Biomet Holdings, Inc. 10-Q filed May 1, 2026

Fiscal Q1 2026 · Period ended Mar 31, 2026 · Filed · accepted 5:11 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 5, 2025: 7 added · 5 removed · 31 modified; 6 with only figures updated

  1. Modified · Results for the Three-Month Period ended March 31, 2026

    In the three and nine-month periods three-month period ended September 30March 31, 20252026, our net sales increased 9.79.3 percent and 5.9 percent, respectively, when compared to the same prior year periodsperiod. Net sales growth was driven by a combination of our Paragon 28 acquisition, market growth, new product introductions, and lower net sales positive effects of changes in the prior year periods due to operational challenges fulfilling foreign currency exchange rates, opportunistic end-of-quarter customer orders as a consequence of a new enterprise resource planning ("ERP") software system implementationpurchases, timing of ROSA® Robot and bone cement sales, market growth and new product introductions. Paragon 28 had a positive impact on our net sales of 3.63.9 percent and 2.1 percent in the three and nine-month periods three-month period ended September 30March 31, 2025, respectively2026. Additionally, our net sales experienced a positive effect of 1.12.5 percent and 0.5 percent from changes in foreign currency exchange rates in the three and nine-month periods three-month period ended September 30March 31, 2025, respectively2026.